Olaf Ortmann

9.9k total citations · 1 hit paper
346 papers, 6.3k citations indexed

About

Olaf Ortmann is a scholar working on Oncology, Genetics and Reproductive Medicine. According to data from OpenAlex, Olaf Ortmann has authored 346 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 109 papers in Genetics and 103 papers in Reproductive Medicine. Recurrent topics in Olaf Ortmann's work include Estrogen and related hormone effects (96 papers), Ovarian function and disorders (45 papers) and Ovarian cancer diagnosis and treatment (42 papers). Olaf Ortmann is often cited by papers focused on Estrogen and related hormone effects (96 papers), Ovarian function and disorders (45 papers) and Ovarian cancer diagnosis and treatment (42 papers). Olaf Ortmann collaborates with scholars based in Germany, United States and Poland. Olaf Ortmann's co-authors include Oliver Treeck, Günter Emons, K. Diedrich, Claus Lattrich, Monika Klinkhammer‐Schalke, Andrew V. Schally, Florian Zeman, Atanas Ignatov, Susanne Schüler‐Toprak and Michael Koller and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer.

In The Last Decade

Olaf Ortmann

310 papers receiving 6.1k citations

Hit Papers

Ki-67 is a prognostic par... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
    2013 434 citations EC Inwald, Monika Klinkhammer‐Schalke et al. Breast Cancer Research and Treatment profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Olaf Ortmann 2.2k 1.7k 1.6k 1.6k 1.1k 346 6.3k
Günter Emons 2.9k 1.3× 1.5k 0.9× 2.0k 1.2× 2.1k 1.4× 819 0.8× 248 7.0k
Christine L. Clarke 1.2k 0.5× 2.1k 1.2× 3.8k 2.3× 2.4k 1.5× 483 0.4× 136 7.0k
Ludwig Kiesel 4.0k 1.8× 1.4k 0.8× 1.0k 0.6× 2.6k 1.7× 1.4k 1.3× 312 9.2k
Kimberly K. Leslie 1.3k 0.6× 1.3k 0.7× 1.2k 0.7× 1.9k 1.2× 378 0.3× 186 5.6k
Takuya Moriya 1.3k 0.6× 2.7k 1.6× 2.1k 1.3× 3.1k 2.0× 304 0.3× 336 9.3k
Udo Jeschke 1.6k 0.7× 1.8k 1.0× 1.1k 0.7× 3.0k 1.9× 975 0.9× 473 8.8k
Satoru Kyo 1.8k 0.8× 1.9k 1.1× 1.9k 1.2× 4.7k 3.0× 387 0.4× 325 10.3k
Äkïhïko Okuyama 2.1k 0.9× 860 0.5× 1.4k 0.8× 3.3k 2.1× 1.3k 1.2× 479 9.4k
R.J.B. King 879 0.4× 1.3k 0.7× 2.9k 1.8× 1.8k 1.2× 335 0.3× 178 5.6k
Hani Gabra 2.2k 1.0× 2.4k 1.4× 986 0.6× 3.2k 2.1× 309 0.3× 174 7.4k

Countries citing papers authored by Olaf Ortmann

Since Specialization
Citations

This map shows the geographic impact of Olaf Ortmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Ortmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Ortmann more than expected).

Fields of papers citing papers by Olaf Ortmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Ortmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Ortmann. The network helps show where Olaf Ortmann may publish in the future.

Co-authorship network of co-authors of Olaf Ortmann

This figure shows the co-authorship network connecting the top 25 collaborators of Olaf Ortmann. A scholar is included among the top collaborators of Olaf Ortmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olaf Ortmann. Olaf Ortmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schoffer, Olaf, Pauline Wimberger, Michael Gerken, et al.. (2024). Treatment in Certified Breast Cancer Centers Improves Chances of Survival of Patients with Breast Cancer. Geburtshilfe und Frauenheilkunde. 84(2). 153–163. 6 indexed citations
2.
Schoffer, Olaf, Pauline Wimberger, Michael Gerken, et al.. (2024). Die Behandlung in zertifizierten Brustkrebszentren verbessert die Überlebenschancen von Patient*innen mit Brustkrebs. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 21(2). 121–131. 1 indexed citations
3.
4.
Kowalski, Christoph, et al.. (2024). Zusammenarbeit von Krebsregistern und zertifizierten Zentren. 30(4). 257–264. 1 indexed citations
5.
Ortmann, Olaf, et al.. (2023). Therapie von menopausalen Symptomenbei Patientinnen mit Krebserkrankungen. 17(2). 173–189.
6.
Schüler‐Toprak, Susanne, Maciej Skrzypczak, Carsten Gründker, Olaf Ortmann, & Oliver Treeck. (2023). Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer. Cancers. 15(10). 2845–2845. 15 indexed citations
7.
Veit, Christof, Simone Wesselmann, Stephanie Stock, et al.. (2022). Versorgungsnahe Daten für Versorgungsanalysen – Teil 3 des Manuals. Das Gesundheitswesen. 85(08/09). 718–724. 6 indexed citations
8.
9.
10.
Scheiter, Alexander, Florian Lüke, Felix Keil, et al.. (2021). STRN-ALKFusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy. JCO Precision Oncology. 5(5). 1507–1513. 4 indexed citations
11.
Wesselmann, Simone, Clara Breidenbach, Jens‐Uwe Blohmer, et al.. (2021). Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers. Journal of Cancer Research and Clinical Oncology. 148(3). 719–726. 1 indexed citations
12.
Wege, Anja K., Nicole Kirchhammer, Michael R. Brandt, et al.. (2020). A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM). Journal of Translational Medicine. 18(1). 316–316. 5 indexed citations
13.
Inwald, EC, Olaf Ortmann, Michael Koller, et al.. (2017). Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. Breast Cancer Research and Treatment. 163(1). 119–130. 26 indexed citations
14.
Wege, Anja K., Florian Weber, Alexander Kroemer, et al.. (2016). IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget. 8(2). 2731–2744. 23 indexed citations
15.
Seitz, Stephan, Stefan Buchholz, Andrew V. Schally, et al.. (2012). Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anti-Cancer Drugs. 24(2). 150–157. 16 indexed citations
16.
Lattrich, Claus, et al.. (2010). Icb-1Gene Expression is Elevated in Human Endometrial Adenocarcinoma and is Closely Associated With HER2 Expression. Cancer Investigation. 28(9). 904–909. 3 indexed citations
17.
Bals‐Pratsch, M., Burkhardt Seifert, & Olaf Ortmann. (2009). Genetic Causes in Adrenal or Ovarian Hyperandrogenism in the Reproductive Years. Journal für Kardiologie (Krause & Pachernegg GmbH). 6(1). 19–23.
18.
Treeck, Oliver, Rong Zhou, Klaus Diedrich, & Olaf Ortmann. (2004). Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells. Anti-Cancer Drugs. 15(8). 787–793. 11 indexed citations
19.
Beckmann, Matthias W., Peter A. Fasching, Johannes M. Weiss, A. Magener, & Olaf Ortmann. (2003). Update primäres Mammakarzinom 2003. Geburtshilfe und Frauenheilkunde. 63(4). 2 indexed citations
20.
Ortmann, Olaf, W. Braendle, Cosima Brucker, et al.. (2003). Konsensusempfehlungen zur Hormontherapie (HT) im Klimakterium und in der Postmenopause - im Auftrag des Vorstands der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. Geburtshilfe und Frauenheilkunde. 10(2). 209–212. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Günter Emons Breakdown of academic impact, for papers by Christine L. Clarke Breakdown of academic impact, for papers by Ludwig Kiesel Breakdown of academic impact, for papers by Kimberly K. Leslie Breakdown of academic impact, for papers by Takuya Moriya Breakdown of academic impact, for papers by Udo Jeschke Breakdown of academic impact, for papers by Satoru Kyo Breakdown of academic impact, for papers by Äkïhïko Okuyama Breakdown of academic impact, for papers by R.J.B. King Breakdown of academic impact, for papers by Hani Gabra
Rankless by CCL
2026